Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Mibefradil is a calcium channel blocker with moderate selectivity for T-type Ca2+ channels (IC50s: 2.7 μM and 18.6 μM for T-type and L-type currents). 在相同实验条件下,摩尔浓度相同的化合物盐形式与游离态具有相同的生物活性,但盐形式 Mibefradil dihydrochloride 的水溶性和稳定性通常比游离态更好。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 17,200 | 10-14周 | ||
50 mg | ¥ 22,800 | 10-14周 | ||
100 mg | ¥ 29,500 | 10-14周 |
Mibefradil 的其他形式现货产品:
产品描述 | Mibefradil is a calcium channel blocker with moderate selectivity for T-type Ca2+ channels (IC50s: 2.7 μM and 18.6 μM for T-type and L-type currents). |
靶点活性 | Ca2+ channel, L-type:18.6 μM, Ca2+ channel, T-type:2.7 μM |
体外活性 | Mibefradil (Ro 40-5967) blocks T-type current already at a holding potential of -100 mV [1]. At a higher concentration (20 μM), Mibefradil reduces the amplitude of excitatory junction potentials (by 37±10 %), slows the rate of repolarisation (by 44 %) and causes a significant membrane potential depolarization (from ?83±1 mV to ?71±5 mV). At a higher Mibefradil concentration (20 μM) there is significant membrane potential depolarization and a slowing of repolarization [2]. |
体内活性 | The hearing thresholds of the 24-26 week old C57BL/6J mice differed following the 4-week treatment period. The hearing threshold at 24 kHz is significantly decreased in the Mibefradil-treated and benidipine-treated groups compared with the saline-treated group [3]. Compared with the saline-treated group, rats receiving Mibefradil show significantly lower CaV3.2 expression in the spinal cord and DRG [4]. |
动物实验 | A total of 30 male C57BL/6J mice (age, 6-8 weeks) are randomized into three groups for the detection of three calcium channel receptor subunits α1G, α1H and α1I, using RT-qPCR. In addition, a further 30 C57BL/6J male mice (age, 24-26 weeks) are allocated at random into three treatment groups: Saline, Mibefradil, and benidipine. Each group is subjected to auditory brainstem recording (ABR) and distortion product otoacoustic emission (DPOAE) tests following treatment. Mibefradil and benidipine are dissolved in a physiological saline solution. A preliminary experiment led to the selection of dosages of 30 mg/kg/day Mibefradil and 10 mg/kg/day Benidipine. The drugs are administered to the mice by gavage for four consecutive weeks [3]. Male Sprague-Dawley rats (200-250 g) are used for right L5/6 SNL to induce neuropathic pain. Intrathecal infusion of saline or TCC blockers [Mibefradil (0.7 μg/h) or Ethosuximide (60 μg/h)] is started after surgery for 7 days. Fluorescent immunohistochemistry and Western blotting are used to determine the expression pattern and protein level of CaV3.2. Hematoxylin-eosin and toluidine blue staining are used to evaluate the neurotoxicity of tested agents [4]. |
别名 | 米贝地尔, Ro 40-5967 |
分子量 | 495.63 |
分子式 | C29H38FN3O3 |
CAS No. | 116644-53-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 95 mg/mL (191.68 mM), Heating is recommended.
Ethanol: 52 mg/mL (104.92 mM), Heating is recommended.
DMSO: 50 mg/mL (100.88 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
H2O / Ethanol / DMSO | 1 mM | 2.0176 mL | 10.0882 mL | 20.1763 mL | 50.4409 mL |
5 mM | 0.4035 mL | 2.0176 mL | 4.0353 mL | 10.0882 mL | |
10 mM | 0.2018 mL | 1.0088 mL | 2.0176 mL | 5.0441 mL | |
20 mM | 0.1009 mL | 0.5044 mL | 1.0088 mL | 2.522 mL | |
50 mM | 0.0404 mL | 0.2018 mL | 0.4035 mL | 1.0088 mL | |
100 mM | 0.0202 mL | 0.1009 mL | 0.2018 mL | 0.5044 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Mibefradil 116644-53-2 Membrane transporter/Ion channel Metabolism Calcium Channel 米贝地尔 Ro 40-5967 Inhibitor inhibitor inhibit